Abstracts Archive - Page 665 of 2607 - ACR Meeting Abstracts

Abstract Number: 1997 • ACR Convergence 2022
Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis
Rebecca Blank¹, Alba Boix-Amoros², Renuka Nayak³, Anthony Jimenez Hernandez¹, Sydney Catron⁴, Zakwan Uddin⁴, Erin Reilly⁵, Andrew Patterson⁵, Peter Turnbaugh⁶, Jose Clemente² and Jose Scher⁷, ¹NYU School of Medicine, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴NYU Langone Health, New York, NY, ⁵Pennsylvania State University, College Park, PA, ⁶UCSF, San Francisco, ⁷New York University School of Medicine, New York, NY
Background/Purpose: The gut microbiome and its metabolites are dysregulated in rheumatoid arthritis. Short chain fatty acids (SCFAs), microbial fermentation byproducts of certain gut microbes, induce…
Abstract Number: 2001 • ACR Convergence 2022
Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data
Tanya Shivacheva, Medical University prof.dr. P. Stoyanov, Varna, Bulgaria, Varna, Bulgaria
Background/Purpose: Sustained targeted therapeutic outcome with biological therapy in real clinical conditions is not yet achievable in a large proportion of rheumatoid arthritis (RA) patients.…
Abstract Number: 1999 • ACR Convergence 2022
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Vibeke Strand¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹Stanford University School of Medicine, Stanford, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
Abstract Number: 2004 • ACR Convergence 2022
Which Route and Dose of Corticosteroids Is Most Effective in Inducing Remission in Early Rheumatoid Arthritis? A Systematic Literature Review and Meta-analysis
Laura Parker¹ and Nicola Gullick², ¹University of Warwick, Coventry, United Kingdom, ²University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom
Background/Purpose: Current NICE guidance for rheumatoid arthritis (RA) states that glucocorticoids may be used for bridging therapy and to rapidly decrease inflammation in acute flares1.…
Abstract Number: 2003 • ACR Convergence 2022
Anti-rheumatic Treatment Modulates Expression of the Glycolytic Enzyme PFKFB3 in CD14+ Monocytes of Patients with Rheumatoid Arthritis, Which Contributes to Dissimilarities of the IFN Signature
Malin Erlandsson¹, Karin Andersson¹, Sofia Töyrä Silfverswärd², Rille pullerits² and Maria Bokarewa², ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Combination of IFN-stimulated genes known as IFN signature, helps to predict disease activity and treatment response in several autoimmune diseases, including rheumatoid arthritis (RA).…
Abstract Number: 2006 • ACR Convergence 2022
Healthcare Resource Utilization and Economic Burden of Patients with Adequate and Inadequate Responses to Advanced Therapies for Rheumatoid Arthritis in Japan
Kei Ikeda¹, Yuko Kaneko², Jayeshkumar Patel³, Toru Yamazaki⁴, Siran Fang³, Tsujita Yuki⁴ and Yutaka Kawahito⁵, ¹Chiba University Hospital, Chiba, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie GK, Tokyo, Japan, ⁵Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan
Background/Purpose: Substantial numbers of patients with RA receiving advanced therapies including biologics, biosimilars, and Janus kinase inhibitors do not achieve ACR50 responses and lack of…
Abstract Number: 2005 • ACR Convergence 2022
Comparison of Treatment and Disease Activity in the Early Stage of Onset in Patients with Elderly-onset vs Younger-onset Rheumatoid Arthritis Using Data of National Database of Rheumatic Diseases in Japan (NinJa)
Toshihiro Matsui¹ and Shigeto Tohma², ¹NHO Sagamihara National Hospital, Kanagawa, Japan, ²National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: To clarify the current status and issues concerning treatment in the early stage of onset in patients with elderly-onset rheumatoid arthritis (RA) in Japan.Methods:…
Abstract Number: 2009 • ACR Convergence 2022
Long-term Outcome of a Treat-to-target Strategy in Elderly-onset Rheumatoid Arthritis with Chronic Lung Diseases
Manami Nomura¹, Takahiko Sugihara², Hiroyuki Baba¹, Tatsuro Ishizaki³, Tadashi Hosoya¹, Mari Kamiya¹, Takumi Matsumoto², Kanae Kubo⁴, Fumio Hirano⁵, Masayo Kojima⁶, Nobuyuki Miyasaka⁵, Shinsuke Yasuda⁵ and Masayoshi Harigai⁷, ¹Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ³Human Care Research Team, Tokyo Metropolitan Institute of Gerontology., Tokyo, Japan, ⁴Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁶Department of Frailty Research, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Nagoya, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
Background/Purpose: Elderly patients with rheumatoid arthritis (RA) tend to have a higher risk for drug-related adverse events (AEs) than younger patients, and the effectiveness and…
Abstract Number: 2008 • ACR Convergence 2022
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs
Alan Kivitz¹, Liangwei Wang², Ilias Alevizos², Michele Gunsior², Judith Falloon² and Gabor Illei³, ¹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ²Horizon Therapeutics, Gaithersburg, MD, ³Horizon Therapeutics, Rockville, MD
Background/Purpose: Dazodalibep (DAZ), a non-antibody biologic antagonist of CD40L, led to higher/durable response rates vs. placebo (PBO) in a double-blind, Phase 1b trial of patients…
Abstract Number: 2007 • ACR Convergence 2022
Rheumatoid Arthritis Associated Lymphoproliferative Disorders: Current Features and It’s Changing Pattern Due to the Influence of Anti-rheumatic Drugs
Yoshihiko Hoshida¹, Atsuko Tsujii², Shiro Ohshima², Yukihiko Saeki², Masato Yagita³, Tomoya Miyamura⁴, Masao Katayama⁵, Yasushi Hiramatsu⁶, Hisaji Oshima⁷, Toshihiko Murayama⁸, Shinji Higa⁹, Fuminori Hirano¹⁰, Kenji Ichikawa¹¹, Noriyuki Chiba¹², Takao Sugiyama¹³, Atsushi Ihata¹⁴, Akiko Mitsuo¹⁵, Hiroshi Tsutani¹⁶, Koichiro Takahi¹⁷, Akira Okamoto¹⁸, Shigeru Yoshizawa¹⁹, Yasuo Suenaga²⁰, Shunsuke Mori²¹, Shoichi Nagakura²², Norie Yoshikawa²³, Atsuhisa Ueda²⁴, Shouhei Nagaoka²⁵, Keigo Setoguchi²⁶, Shoji Sugii²⁷, Asami Abe²⁸, Toshiaki Sugaya²⁹, Masahiro Koseto³⁰, Yasuo Kunugiza³¹, Norishige Iizuka³², Ryosuke Yoshihara³³, Tomoaki Fujisaki³⁴, Hiroyuki Sugahara³⁵, Ikuo Saito³⁶, Kazuya Kuraoka³⁷, Norihiro Teramoto³⁸, Masahiro Ito³⁹, Kenichi Taguchi⁴⁰, Yuko Minami⁴¹, Shinji Naito⁴², Mitsuharu Nomoto⁴³, Kazuyoshi Saito⁴⁴, Kiyoshi Matsui⁴⁵, Yasuhiko Tomita⁴⁶, Hiroshi Furukawa⁴⁷ and Shigeto Tohma⁴⁸, ¹Department of Pathology, NHO Osaka Minami Medical Center, Kawachinagano, Japan, ²Department of Rheumatology, NHO Osaka Minami Medical Center, Kawachinagano, Japan, ³Division of Inflammation and Immunity, Tazuke-Kofukai Medical Research Institute Kitano Hospital, Osaka, Osaka, Japan, ⁴Department of Rheumatology, NHO Kyushu Medical Center, Fukuoka, Japan, ⁵Department of Rheumatology, NHO Nagoya Medical Center, Nagoya, Japan, ⁶Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁷National Hospital Organization Tokyo Medical Center, Meguroku, Japan, ⁸Department of Pathology, NHO Kumamoto Medical Center, Kumamoto, Kumamoto, Japan, ⁹Division of Rheumatology, Daini Osaka Police Hospital, Osaka, Osaka, Japan, ¹⁰Department of Rheumatology, NHO Asahikawa Medical Center, Asahikawa, Hokkaido, Japan, ¹¹Department of Rheumatology, NHO Hokkaido Medical Center, Sapporo, Japan, ¹²epartment of Rheumatology, NHO Morioka Medical Center, Morioka, Japan, ¹³Department of Rheumatology, NHO Shimoshizu Hospital, SIkaido, Chiba, Japan, ¹⁴Department of Rheumatology, NHO Yokohama Medical Center, Yokohama, Japan, ¹⁵Department of Rheumatology, NHO Disaster Medical Center, Tachikawa, Japan, ¹⁶Department of Rheumatology, NHO Awara Hospital, Awara, Fukui, Japan, ¹⁷Department of Rheumatology, NHO Osaka Toneyama Medical Center, Toyonaka, Japan, ¹⁸Department of Rheumatology, NHO Himeji Medical Center, Himeji, Japan, ¹⁹Department of Rheumatology, NHO Fukuoka Hospital, Fukuoka, Japan, ²⁰Department of Rheumatology, NHO Beppu Medical Center, Beppu, Oita, Japan, ²¹Department of Rheumatology, NHO Kumamoto Saishun Medical Center, Goshi, Japan, ²²Department of Hematology, NHO Kumamoto Minami Hospital, Ushiro, Japan, ²³Department of Rheumatology, NHO Miyakonojo Medical Center, Miyakonojo, Japan, ²⁴Department of Rheumatology, Yokohama City University, Yokohama, Japan, ²⁵Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ²⁶Department of Systemic immunological diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, ²⁷Department of Internal Medicine, Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, ²⁸Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²⁹Department of Rheumatology, Fuchu Hospital, Izumi, Japan, ³⁰Department of Laboratory Medicine and Internal Medicine (Clinical Immunology), Nippon Life Hospital, Osaka, Osaka, Japan, ³¹Department of Orthopedics, JCHO Hoshigaoka Medical Center, Hirakata, Japan, ³²Department of Pathology, Kishiwada City Hospital, Kishiwada, Japan, ³³Department of Rheumatology, Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, ³⁴Department of Hematology, Matsuyama Red Cross Hospital, Matsuyama, Japan, ³⁵Department of Hematology, Sumitomo Hospital, Osaka, Osaka, Japan, ³⁶Department of Pathology, NHO Sagamihara Hospital, Sagamihara, Kanagawa, Japan, ³⁷Department of Diagnostic Pathology, NHO Kure Medical Center /Chugoku Cancer Center, Kure, Hiroshima, Japan, ³⁸Department of Pathology, NHO Shikoku Cancer Center, Matsuyama, Japan, ³⁹Department of Pathology, NHO Nagasaki Medical Center, Nagasaki, Japan, ⁴⁰Department of Pathology, NHO Kyushu Cancer Center, Fukuoka, Japan, ⁴¹Department of Pathology, NHO Ibarakihigashi Hospital, Nakagun, Japan, ⁴²Department of Pathology, NHO Ureshino Medical Center, Ureshino, Japan, ⁴³Department of Pathology, NHO, Kagoshima Medical Center, Kagoshima, Japan, ⁴⁴First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴⁵Hyogo College of Medicine, Nishinomiya, Japan, ⁴⁶Department of Pathology, International University of Health and Welfare, Narita, Japan, ⁴⁷Department of Rheumatology, NHO Tokyo National Hospital, Tokyo, Japan, ⁴⁸National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: The effect of antirheumatic drugs on the development of lymphoproliferative disorders (LPDs) in rheumatoid arthritis (RA) patients remains unclear. The current study aimed to…
Abstract Number: 1995 • ACR Convergence 2022
Baricitinib Improves Bone Biomechanical Properties in Rheumatoid Arthritis (RA) – Results of a Prospective Interventional Study
Stephan Kemenes¹, Koray Tascilar², David Simon¹, Sara Bayat³, Gerhard Kroenke², Larissa Valor Mendez², Fabian Hartmann⁴, Louis Schuster⁴, Anna-Maria Liphardt¹, Georg Schett⁵ and Arnd Kleyer², ¹Department of Internal Medicine 3, Rheumatoloy and Immunology, University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ⁴University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ⁵Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Deterioration of peripheral bone mass and bone biomechanics are well-known consequences of Rheumatoid Arthritis (RA)[1]. CCP-AB pos. RA, in particular, leads to a significant…
Abstract Number: 1922 • ACR Convergence 2022
Multi-Joint Osteoarthritis Phenotypes by Race/Ethnicity and Sex: Preliminary Descriptive Data from the Johnston County Health Study
Sherwin Novin¹, Carolina Alvarez², Todd Schwartz³, Yvonne Golightly⁴ and Amanda Nelson², ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To describe phenotypes of multi-joint osteoarthritis (MJOA) definitions by race/ethnicity and sex in a community-based cohort.Methods: The Johnston County Health Study (JoCoHS) is an…
Abstract Number: 1826 • ACR Convergence 2022
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
Sandra Hermann¹, Andriko Palmowski¹, Bukrhard Muche², Kay-Geert Hermann³, Edgar Wiebe¹ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…
Abstract Number: 1633 • ACR Convergence 2022
Genetic Risk, Adherence to a Healthy Lifestyle, and Incident Gout in US Women and Men
Kehuan Lin¹, Natalie McCormick¹, Leo Lu², amit johi³, Chio Yokose⁴ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Regeneron, Boston, MA, ⁴Massachusetts General Hospital, Waltham, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Lifestyle and genetic factors have been independently related to incident gout risk. However, it remains unknown whether the genetic risk of gout is affected…
Abstract Number: 2016 • ACR Convergence 2022
Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Abelina Schneider³, Anne Pankow³, Linda Hartman⁴, Jose Pereira da Silva⁵, John Kirwan⁶, Siegfried Wassenberg⁷, Christian Dejaco⁸, Robin Christensen⁹, Maarten Boers¹⁰ and Frank Buttgereit¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, ⁵University of Coimbra, Rheumatology, Columbia, Portugal, ⁶University of Bristol, Bristol, United Kingdom, ⁷Rheumazentrum Ratingen, Ratingen, Germany, ⁸Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].